Acquisition of drug resistance should impose a cost on bacteria. Recent studies, however, suggest that natural selection acts to reduce, or eliminate, the growth disadvantage of resistant bacteria, making it difficult to reverse the high levels of antibiotic resistance currently found in hospitals and the community.
Sixty years of antibiotic usage has provided an unfortunate example of a massive experiment in microbial evolution under intense selection. The development of antibiotics, from the sulphonamides of the 1930s to the powerful broad spectrum antibiotics of today, has replaced Erhlich's concept of the magic bullet with that of the shot gun, and has led to a fundamental disturbance of microbial ecology. The bacteria found within many hospitals are very different from those of the pre-antibiotic era, as increasingly antibiotic-resistant strains of the perennially important pathogens have replaced their antibiotic-susceptible forebears [1] . The eradication of the normal flora by powerful antibiotics has also led to the rise in prominence of intrinsically antibiotic-resistant species that previously rarely caused disease, but which can flourish when the microbial ecology is grossly disturbed [1] . Similar problems with antibiotic resistance are increasingly found with many of the community-acquired pathogens.
The extent of antibiotic resistance is strongly correlated with the level of antibiotic usage. A reduction in antibiotic usage within hospitals and the community is frequently urged, as it is believed that the ecological disturbance caused by antibiotic overuse can be reversed. Antibioticresistant isolates are considered to grow more slowly than antibiotic-susceptible ones (the 'cost' of resistance), resistant bacteria persisting only as a consequence of frequent selection applied by antibiotic usage. Theory, however, suggests that bacteria should adapt to eliminate the cost of resistance, and laboratory experiments confirm this expectation [2] . Acquisition of antibiotic-resistance plasmids, or the introduction of chromosomal mutations that provide antibiotic resistance, does initially reduce the growth rate of bacteria [2] [3] [4] . But Bouma and Lenski [3] found that growth of Escherichia coli containing the drug resistance plasmid pACYC184 for 500 generations, with selection for maintenance of the plasmid, resulted in adaptation of the host to eliminate the cost of plasmid carriage. The most surprising aspect of this work was that the adapted E. coli host containing pACYC184 had a competitive advantage over the original plasmid-free E. coli host even when grown in the absence of antibiotic. Thus, selection for increased fitness during long-term growth resulted in a strain that actually grows better with pACYC184 than without.
Similarly, Schrag and Perrot [4] recently reported that streptomycin-resistant mutants of E. coli, with either of two different mutations in rpsL -which encodes a ribosomal protein -had a growth disadvantage of 14 % and 19 % per generation compared with their parent strain. Growth of the resistant strains for 180 generations, in the absence of streptomycin, resulted in faster growing variants that had only a slight growth disadvantage relative to their streptomycin-susceptible parent. Contrary to expectations, these variants had not reduced the cost of resistance by back mutations at rpsL, but had a second site mutation(s) that increased their growth rate, without loss of streptomycin resistance. Having adapted to the rpsL mutations, there was now a fitness cost of losing streptomycin resistance (S.J. Schrag, V. Perrot and B.R. Levin, personal communication). The implication is that resistance to streptomycin by ribosomal alterations may initially slow growth, but secondary mutations quickly arise that eliminate this cost, producing fitter variants in which reversion to antibiotic-susceptibility may now be costly.
If selection also acts to eliminate the cost of resistance in clinical isolates, and may even produce variants in which loss of resistance is detrimental, attempts to eliminate resistance to an antibiotic by prohibiting the prescription of that antibiotic will be frustrated. An important additional factor that makes it difficult to eliminate resistance in clinical isolates is the frequent occurrence of multiply antibiotic-resistant bacteria: restrictions on the use of one antibiotic will have negligible effect if the other antibiotics to which the bacteria are resistant are still in use. A low cost of resistance in the absence of antibiotics, but very strong selection for resistance in the presence of antibiotics, would be unfortunate, as an antibiotic-resistant flora that develops after antibiotic use will take a long time to reduce to the very low levels (close to zero) that are required to prevent the resistant flora re-emerging when the next course of antibiotic is prescribed. If the cost of resistance is low, complete eradication of resistant bacteria may only be possible if the time between courses of antibiotics is very long (Fig. 1) .
There are few reports that directly address the cost of resistance in natural populations, and most of the evidence is indirect and anecdotal. However, the idea that bacteria frequently exposed to antibiotic may adapt to eliminate the cost of carrying a drug resistance plasmid was proposed from studies of antibiotic resistance levels in pigs over 20 years ago, as there was no significant reduction in the percentage of pigs harbouring tetracycline resistance plasmids four years after the use of tetracycline as a feed additive was banned in the UK [5] . Rapid adaptation to the cost of plasmid carriage also appears to have occurred in penicillin-resistant isolates of Neisseria gonorrhoeae, which arose in 1976 when a plasmid encoding the penicillin-degrading enzyme ␤-lactamase entered this species. In very early isolates, the plasmid was extremely unstable, and was rapidly lost if the bacteria were grown in the absence of penicillin. However, the plasmid was much more stable in isolates recovered only a few months later, and is rarely lost from current isolates, even in the absence of antibiotic selection ( [6] 
and M. Roberts, personal communication).
A more general argument suggests that the cost of resistance in clinical isolates cannot be high. Antibiotic usage in hospitals may provide enough selection to maintain antibiotic-resistant bacteria, even if there were a significant cost to resistance. It is unlikely, however, that a high cost of resistance would allow antibiotic-resistant bacteria to compete successfully within the community where antibiotic usage is much less than in hospitals. In many cases antibiotic-resistant bacteria clearly do compete very successfully in the community. For example, a high incidence of antibiotic resistance has been found in the faecal flora of individuals who have not been hospitalized or taken antibiotics during the last three months [7] . Similarly, in many countries, antibiotic resistance is common among the oral and nasopharyngeal flora of individuals in the community.
What can be done? Reduction in antibiotic usage is still essential. Although this may not have much effect within hospitals, where multiple antibiotic resistance is common and antibiotic usage will inevitably remain high, a reduction in usage (effectively, an increase in the average interval between courses of antibiotic) may decrease the extent of resistance in the community, and should slow the further development of resistance. New vaccines are certainly needed to prevent specific infections, but they cannot replace antibiotics which have the potential to cure all bacterial infections. The most pressing need is for a number of truly novel antibiotics that have activity against the problem pathogens, and for a policy to restrict severely the use of new compounds to delay the development of resistance. If this is not achieved, the golden age of antibiotics is over. Surprisingly, no major new class of antibiotics has been developed for over 15 years, and several years ago some of the major pharmaceutical companies stopped research into novel antibacterials. This situation may be changing for two main reasons. Firstly, the genome sequences of most of the major bacterial pathogens will be available within a few years, providing a plethora of potential new targets for the design of novel antibiotics. Secondly, the Achilles heel of current antibiotics has been that they are developed from lead compounds, uncovered by screening for antibacterial activity within soil samples. For most of these natural product antibiotics, the major problem has been the rapid appearance of genes encoding enzymes that inactivate them, or which protect their targets from inhibition. These antibiotic-resistance genes are believed to be derived from genes that evolved long ago to protect the antibiotic-producing soil microorganisms from their own antibiotics [8] .
This problem may now be circumvented by using combinatorial chemistry to provide large numbers of chemicals to assay for activity against the novel target enzymes arising from genome sequencing projects. In this way, it is hoped that antibiotics will be produced for which there are no pre-existing resistance genes. Resistance should then develop mainly by target mutations that reduce affinity, or by increased activity of efflux systems. The development of resistance is inevitable, but our substantial knowledge of the mechanisms of resistance to pre-existing antibiotics should allow a rational choice of those bacterial targets where resistance is likely to emerge most slowly [9] . Decrease in the relative abundance of antibiotic-resistant to antibioticsusceptible bacteria in the absence of antibiotics, as a function of the cost of resistance. m R and m S are the growth rates of the resistant and susceptible bacteria, respectively; m S is set at 4.6 generations per day. The change in the ratio of resistant to susceptible bacteria is shown for a 1 % (blue line) and a 10 % (red line) cost of antibiotic resistance. The time taken to reduce the abundance of resistant bacteria to some low level is inversely related to the cost of resistance. Thus, reduction in the initial cost of antibiotic resistance from 10 % to 1 % will increase the time taken to eliminate resistant bacteria by a factor of ten. 
